Cyclacel Pharmaceuticals ... (CYCC)
NASDAQ: CYCC
· Real-Time Price · USD
6.37
-0.40 (-5.91%)
At close: Sep 11, 2025, 3:59 PM
Cyclacel Pharmaceuticals Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
Cash & Equivalents | 3.14M | 3.38M | 18.34M | 36.56M |
Short-Term Investments | n/a | n/a | n/a | n/a |
Long-Term Investments | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 411K | 1.26M | 3.46M | 1.55M |
Receivables | 237K | 2.93M | 4.66M | 3.73M |
Inventory | n/a | n/a | n/a | 577K |
Other Current Assets | 63K | 341K | 426K | -498K |
Total Current Assets | 3.67M | 7.44M | 24.41M | 40.94M |
Property-Plant & Equipment | 8K | 102K | 174K | 94K |
Goodwill & Intangibles | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 419K | 1.36M | 3.64M | 1.65M |
Total Assets | 4.09M | 8.8M | 28.05M | 43.14M |
Account Payables | 4.6M | 3.54M | 2.56M | 2.12M |
Deferred Revenue | n/a | n/a | n/a | n/a |
Short-Term Debt | n/a | n/a | n/a | n/a |
Other Current Liabilities | 283K | 380K | 1.01M | 753K |
Total Current Liabilities | 6.27M | 8.16M | 7.51M | 5.41M |
Long-Term Debt | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a |
Total Long-Term Liabilities | n/a | 37K | 106K | 30K |
Total Liabilities | 6.27M | 8.2M | 7.62M | 5.44M |
Total Debt | n/a | 37K | 106K | 30K |
Book Value | -2.17M | 607K | 20.43M | 37.69M |
Book Value Per Share | -0.26 | 0.76 | 27.23 | 63.34 |
Common Stock | 9K | 1K | 1K | 10K |
Retained Earnings | -439.49M | -428.28M | -405.73M | -384.53M |
Comprehensive Income | -891K | -908K | -1.32M | -748K |
Shareholders Equity | -2.17M | 607K | 20.43M | 37.69M |
Total Investments | n/a | n/a | n/a | n/a |